What is Curis?
Headquartered in Lexington, Massachusetts, Curis, Inc. operates at the intersection of innovation and precision medicine. The firm is dedicated to the discovery, development, and commercialization of targeted cancer therapeutics. Its current clinical focus is anchored by emavusertib, an oral IRAK4 kinase inhibitor, and fimepinostat, a dual HDAC and PI3K inhibitor. These assets represent a sophisticated portfolio aimed at treating complex conditions such as diffuse large B-cell lymphoma and various relapsed or refractory hematologic malignancies. Through strategic collaborations with entities like Aurigene Discovery Technologies, Curis continues to refine its immuno-oncology programs, positioning itself as a vital contributor to the evolving landscape of precision oncology.
How much funding has Curis raised?
Curis has raised a total of $153.3M across 6 funding rounds:
Corporate Investment
$8M
Debt
$30M
Stock Offering
$64.7M
Share Placement
$30M
Debt
$350K
Private Equity
$20.2M
Corporate Investment (2010): $8M with participation from Debiopharm
Debt (2012): $30M led by Pharmakon Advisors
Stock Issuance/Offering (2015): $64.7M supported by Undisclosed
Share Placement (2020): $30M featuring Aspire Capital Limited
Debt (2020): $350K backed by PPP
Private Equity (2026): $20.2M with participation from Nantahala Capital Management and Stonepine Capital Management
Key Investors in Curis
Nantahala Capital Management
A fundamentally-driven alternative investment firm specializing in micro-cap stocks with a multi-year horizon and a focus on alpha generation.
Stonepine Capital Management
An investment management firm dedicated to the life sciences sector, providing private capital and operational expertise to biotechnology companies.
Debiopharm
The investment division of Debiopharm Group, focused on safeguarding capital and generating consistent financial returns through private equity and strategic investments.
What's next for Curis?
With the successful closure of this major strategic investment, Curis is well-positioned to advance its clinical programs through critical development milestones. The capital will likely be deployed to bolster ongoing clinical trials and expand the reach of its proprietary kinase inhibitor platforms. As the company navigates the complexities of late-stage drug development, the focus will remain on generating robust clinical data to support potential regulatory filings and commercialization efforts. By maintaining its focus on high-impact therapeutic areas, Curis is poised to strengthen its market position and deliver significant value to both patients and stakeholders in the competitive biotechnology ecosystem.
See full Curis company page
